Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of Medical Research (ICMR) to initiate Phase 2 clinical trials of Desidustat in patients with Sickle Cell Disease.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
